Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24454
Title: | Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study | Authors: | Baecke, C. GYSSENS, Inge Decoutere, L. VAN DER HILST, Jeroen MESSIAEN, Peter |
Issue Date: | 2017 | Publisher: | VAN ZUIDEN COMMUNICATIONS | Source: | NETHERLANDS JOURNAL OF MEDICINE, 75(6), p. 235-240 | Abstract: | Background: Antiretroviral agents pose a high risk for drug-drug interactions (DDIs), mainly but not limited to being a substrate, inducer or inhibitor of P450 cytochrome enzymes. In part metabolised by other pathways, integrase inhibitors might show a more favourable profile. The aim of this study was to investigate the prevalence of DDIs in daily clinical practice for patients starting different antiretroviral treatment (ART) regimens. Methods: All patients starting ART in our centre from January 2009 to April 2016 were included. All prescribed co-medications since the start of ART were recorded retrospectively from the medical files and screened for DDIs using the Liverpool HIV drug interaction database. Only DDIs between antiretroviral and non-antiretroviral drugs were considered. Results: We included 145 patients, of which 42% were on an integrase inhibitor-based regimen, mainly dolutegravir and elvitegravir. Of the patients, 78% (n = 113) took co-medication. Potential DDIs were seen in 63% of the patients with co-medication; contraindicated prescriptions were detected in 1%. Protease inhibitor-based ART was a risk factor for DDI (odds ratio (OR) 2.57; 95% confidence interval (CI) 1.06-6.19), in contrast to non-nucleoside reverse transcriptase inhibitor-based ART (OR 0.77; 95% CI 0.32-1.84). Concerning integrase inhibitors, a significantly lower risk was seen with dolutegravir-based treatment (OR 0.35; 95% CI 0.15-0.82), though not for elvitegravir-based ART (OR 2.51; 95% CI 0.66-9.58). Conclusions: ART regimens pose a dissimilar risk for drug-drug interactions in clinical practice. Regarding the use of integrase inhibitors, a significantly lower risk was seen with dolutegravir-based treatment. | Notes: | [Baecke, C.; Gyssens, I. C.; van der Hilst, J. C. H.; Messiaen, P.] Jessa Hosp, Dept Infect Dis & Immun, Hasselt, Belgium. [Gyssens, I. C.; van der Hilst, J. C. H.; Messiaen, P.] Hasselt Univ, BIOMED Res Inst, Hasselt, Belgium. [Gyssens, I. C.] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Nijmegen, Netherlands. [Decoutere, L.] Jessa Hosp, Dept Clin Pharm, Hasselt, Belgium. | Keywords: | HIV integrase inhibitors; raltegravir; elvitegravir; dolutegravir; drug-drug interaction;HIV integrase inhibitors; raltegravir; elvitegravir; dolutegravir; drug-drug interaction | Document URI: | http://hdl.handle.net/1942/24454 | Link to publication/dataset: | http://www.njmonline.nl/getpdf.php?id=1869 | ISSN: | 0300-2977 | e-ISSN: | 1872-9061 | ISI #: | 000408099500003 | Rights: | (C) Van Zuiden Communications B.V. All rights reserved. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2018 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
getpdf.pdf | Published version | 186.29 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
22
checked on Oct 15, 2024
Page view(s)
18
checked on Jun 14, 2022
Download(s)
4
checked on Jun 14, 2022
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.